You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 116 No. 11, November 1998 TABLE OF CONTENTS
  Archives
  •  Online Features
  Laboratory Sciences
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Glaucoma
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Effect of Ticrynafen on Aqueous Humor Dynamics in Monkeys

Mary Ann Croft, MS; Rong Fang Wang, MD; Steven M. Podos, MD; Arthur H. Neufeld, PhD; Paul L. Kaufman, MD

Arch Ophthalmol. 1998;116:1481-1488.

Objective  To determine the effect of ticrynafen, a non–sulfhydryl-reactive compound similar to ethacrynic acid, on outflow facility in normotensive monkey eyes and on intraocular pressure (IOP) in monkey eyes with laser-induced glaucoma.

Methods  In normotensive eyes, facility (perfusion) was measured shortly before and after bolus or exchange intracameral infusion of ticrynafen or vehicle in opposite eyes, and 3.5 to 4.5 hours after 5 days of twice-daily 2% ticrynafen or vehicle ointment. In glaucomatous eyes, baseline and vehicle diurnal IOP curves were established, 2% ticrynafen ointment was given twice daily for 5 days, and IOP was measured immediately before and 0.5 to 6 hours after each morning treatment.

Results  In normotensive eyes, exchange 2-mL infusion of 0.2-, 1-, or 4-mmol/L ticrynafen increased facility by 33%±6% (mean±SEM), 73%±18%, and 60%±11%, respectively. Day 5 posttreatment facility was higher in the ticrynafen group than in controls by 28%±9%. In glaucomatous eyes, maximum IOP decline, from approximately 35 mm Hg, was 7.5±2.0 mm Hg on day 4 and 9.8±2.4 mm Hg on day 5 of twice-daily ticrynafen treatment.

Conclusion  The facility-increasing, IOP-lowering action of ticrynafen, ethacrynic acid, and derivatives may not depend entirely on sulfhydryl reactivity.

Clinical Relevance  Whether such drugs as ethacrynic acid and ticrynafen prove valuable for glaucoma therapy, at the least they are useful probes to study aqueous outflow mechanisms.


From the Departments of Ophthalmology and Visual Sciences, University of Wisconsin Medical School, Madison (Ms Croft and Dr Kaufman), Mt Sinai School of Medicine, New York, NY (Drs Wang and Podos), and Washington University Medical School, St Louis, Mo (Dr Neufeld).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1998 American Medical Association. All Rights Reserved.